(RLMD) – Relmada Therapeutics’s Earnings Outlook


Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here’s what investors need to know before the announcement.

Analysts estimate that Relmada Therapeutics will report an earnings per share (EPS) of $-1.83.

Relmada Therapeutics bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company missed EPS by $0.84, which was followed by a 11.07% drop in the share price the next day.

Here’s a look at Relmada Therapeutics’s past performance and the resulting price change:

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate -1.60 -1.47 -1.39 -1.16
EPS Actual -2.44 -1.56 -1.34 -1.28
Price Change % -11.07% 3.43% -0.33% -7.19%

Stock Performance

Shares of Relmada Therapeutics were trading at $22.81 as of March 21. Over the last 52-week period, shares are down 27.52%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.

If you want to track all upcoming earnings announcements, check out our Earnings Calendar here

This article was generated by Benzinga’s automated content engine and reviewed by an editor.



Source link

Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Chat
Loading the chat ...